The GLP-1 conversation has moved quickly.
First, it was about diabetes. Then obesity and weight loss took centre stage. More recently, the conversation has moved into food, protein, nutrition and how reduced appetite could change what consumers eat.
All of those matters. But I think the bigger shift is still ahead of us.
GLP-1 may not simply create a new drug market or even a new nutrition category. It could create an entirely new consumer-health journey, with different needs before treatment, during treatment and after significant weight loss.
That distinction matters. Because if we look only at the person taking the medicine today, we may miss the consumer they are becoming tomorrow.
Before GLP-1: the consumer is already looking for answers
The journey doesn’t really begin with the prescription.
Long before that, someone may already be trying to lose weight, manage blood sugar, improve metabolic health or understand why conventional diet and exercise haven’t delivered the expected results.
They search online. Change diets. Try supplements. Join fitness programmes. Speak to doctors. Perhaps undergo diagnostics.
There is already a consumer-health ecosystem around them. GLP-1 enters somewhere in the middle of this journey. That should change how healthcare companies think about the opportunity.
Instead of asking only, “Who is eligible for treatment?”, perhaps we should also ask, “What was this consumer trying to achieve before treatment began?”
The answer could tell us much more about what they will need later.
During treatment: the need changes
Once treatment begins, the consumer’s relationship with food and nutrition can change considerably.
Appetite may reduce. Portions may become smaller. Some consumers may experience gastrointestinal discomfort. At the same time, maintaining adequate protein, micronutrients, hydration and muscle mass becomes important.
This part of the story is already beginning to receive attention.
And rightly so. But nutrition shouldn’t be reduced to putting a “GLP-1 friendly” label on products. Different consumers will need different solutions.
A 35-year-old working professional losing weight may have very different nutritional and lifestyle needs from a 60-year-old person managing diabetes and trying to preserve muscle.
An Indian vegetarian consumer may need a different solution again.
This is where consumer healthcare thinking becomes relevant. The question isn’t simply what product can be sold alongside GLP-1.
It is what support makes the treatment journey healthier, easier and more sustainable.
That’s a much better place to start.
After weight loss: perhaps the least understood consumer
This may eventually become the most interesting part of the ecosystem.
What happens when the consumer reaches the desired weight? The treatment journey may change, but the health journey doesn’t suddenly end. Weight needs to be maintained.Muscle needs to be preserved.
Eating behaviour may need to change again.
Physical activity becomes important. So does metabolic health. For some consumers, psychological and behavioural support may matter just as much as nutrition.
And there is another question companies will eventually have to confront.
What happens if treatment is reduced, changed or discontinued?
Appetite can return. Old habits can return too. Suddenly, the challenge is no longer weight loss.
It is weight-loss maintenance.
That creates a very different consumer need. This isn’t one market. It could be several connected markets.
This is why I believe GLP-1 needs to be viewed through a wider lens.
Before treatment, the ecosystem could involve screening, diagnostics, medical consultation and metabolic-health assessment.
During treatment, it could involve medical supervision, nutrition, protein adequacy, digestive support, hydration, exercise and monitoring.
After weight loss, the emphasis may move towards muscle preservation, healthy eating, behavioural support, physical activity and long-term metabolic health.
The same person moves through all three.
But their needs keep changing. That makes the opportunity fundamentally different from building another healthcare category around one product.
We are potentially looking at a continuum of consumer health.
No company can own the whole journey
And perhaps it shouldn’t try.
Pharmaceutical companies understand medicines, evidence and disease management. Nutrition companies understand food and formulation. Consumer healthcare companies understand self-care, accessibility and everyday behaviour. Digital-health companies can help with monitoring and personalisation. Doctors, nutritionists and exercise professionals bring something none of these companies can replace: human judgement.
The opportunity may therefore lie in connecting these capabilities. Not necessarily through acquisitions or massive integrated platforms. Sometimes simple partnerships could be enough.
A treatment programme linked to nutritional counselling.
A diagnostic platform connected with metabolic-health monitoring.
Nutrition designed around different stages of the weight-management journey
Digital tools helping consumers maintain progress after treatment.
The ecosystem becomes more valuable when the pieces speak to each other.
India cannot simply import the Western GLP-1 playbook
This point deserves more attention. India’s food habits, protein consumption, affordability, family structures and healthcare access are different.
So is our metabolic-health burden. Solutions built for Western consumers cannot simply be repackaged and brought here.
The Indian opportunity may lie in familiar foods with better nutritional density. Affordable protein formats. Smaller servings. Vegetarian solutions. Better access to dietitians. Digital support in local languages.
Perhaps even combinations we haven’t considered yet. The innovation will come from understanding the Indian consumer journey, not merely following the global product pipeline.
One boundary must remain clear
There will be commercial excitement around GLP-1. That is inevitable.
But this is not simply another lifestyle trend.
These are prescription therapies used for medical conditions.
That places a greater responsibility on every company entering the surrounding ecosystem.
Claims need evidence. Communication needs restraint. And consumer support should complement medical care, not pretend to replace it.
As more products enter this space, trust may become harder to earn. Which is precisely why it may become more valuable.
GLP-1 started by changing how we treat diabetes and obesity. Its next impact may be much broader. It could change how consumers think about nutrition, weight maintenance, muscle health, metabolic health and long-term self-care.
So perhaps the question for pharma, nutrition and consumer healthcare companies isn’t:
What can we sell to a GLP-1 user?
A better question is:
What will this person need before treatment, during treatment and long after the weight has come off?
That is where the real consumer-health ecosystem begins.